🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing around the world, with figures suggesting more than 82 million new cases annually. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the context of rising global incidence, the spread of superbugs and the very limited available drugs presently on offer.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in close succession. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This authorization represents a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

According to results published in a prominent scientific publication, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which combines two antibiotics. The trial involved over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced positive views. The availability of a one-pill regimen of this kind is seen as a "critical tool" for managing the epidemic. This is viewed as crucial to reduce the burden of the disease for patients and to stop the proliferation of untreatable gonorrhoea around the world.